Investigating the ATR inhibitor elimusertib in advanced solid tumors

TRESR trial: Novel ATR inhibitor, RP-3500, for advanced solid tumorsПодробнее

Dr Timothy Yap Reiterates the Unmet Medical Need for Molecularly Targeted Agents in Solid TumorsПодробнее

Background of the KEYLYNK-007 trial for advanced solid tumoursПодробнее

Oncotarget: ATR Inhibition Reverses Cancer Cell Resistance to TemozolomideПодробнее

Phase I study of the ATR inhibitor M1774 in patients with solid tumorsПодробнее

Dr. Sessa Discusses ATR Inhibitors in BRCA-Mutated TumorsПодробнее

PATRIOT: ATR inhibitor monotherapy in advanced solid tumorsПодробнее

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted DeliveryПодробнее

Two Drugs Targeting DNA Damage Response Show Promise in Ongoing Cancer TrialsПодробнее

Treating metastatic solid tumors and urothelial carcinoma with the oral AHR inhibitor, IK-175Подробнее

The future of cellular therapies for solid tumorsПодробнее

BASECAMP-1: progress in developing CAR-T cell therapy for solid tumorsПодробнее

AC21 - Timothy Yap: DNA Damage RepairПодробнее

Update on PETRA trial investigating a next-generation PARP1 select inhibitorПодробнее

New Solid Tumors Clinical Trial: BMS-986315 for Solid Tumors, Advanced Solid TumorsПодробнее

Treating AKT1/3-mutated solid tumors with temsirolimus in the TAPUR trialПодробнее

Phase I/II trial of elraglusib in solid tumorsПодробнее

The future of AdAPT-001 in patients with solid tumors refractory to checkpoint inhibitorsПодробнее

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее